Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTKWFB8)

• DTT Name: Catechol-O-methyl-transferase (COMT) DTT Info
• Gene Name: COMT

Molecule-Related Drug & Molecule List

3 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Entacapone	DMLBVKQ	Parkinson disease	8A00.0	Approved	[1]
Opicapone	DM1BKA6	Parkinson disease	8A00.0	Approved	[2]
Tolcapone	DM8MNVO	Parkinson disease	8A00.0	Approved	[3]

2 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BIA 3-202	DMG3ON2	Parkinson disease	8A00.0	Phase 2	[4]
CGP-28014	DMYNTQV	Major depressive disorder	6A70.3	Phase 2	[5]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nitecapone	DMSJYEX	Pain	MG30-MG3Z	Discontinued in Phase 2	[6]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PGX-200097	DM1A2UI	Schizophrenia	6A20	Preclinical	[7]

8 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(3,4-DIHYDROXY-2-NITROPHENYL)(PHENYL)METHANONE	DMTB41W	Discovery agent	N.A.	Investigative	[8]
1-(3,4-dihydroxy-2-nitrophenyl)-2-phenylethanone	DM9M5D1	Discovery agent	N.A.	Investigative	[9]
1-(3,4-dihydroxy-5-nitrophenyl)-2-phenoxyethanone	DMKI719	Discovery agent	N.A.	Investigative	[10]
3,5-Dinitrocatechol	DMBGSHD	Discovery agent	N.A.	Investigative	[11]
5,6-dihydroxy-7-nitro-2,3-dihydroinden-1-one	DM94V8D	Discovery agent	N.A.	Investigative	[9]
6,7-dihydroxy-8-nitro-1-tetralone	DM9JLUS	Discovery agent	N.A.	Investigative	[9]
7,8-dihydroxy-4-phenyl-2H-chromen-2-one	DMUB5E8	Discovery agent	N.A.	Investigative	[8]
BIA	DM4RZ9A	Non-insulin dependent diabetes	5A11	Investigative	[8]

References

• [1] Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. Clin Ther. 2001 Jun;23(6):802-32; discussion 771.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [3] Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22.
• [4] Chemical synthesis and characterization of conjugates of a novel catechol-O-methyltransferase inhibitor. Bioconjug Chem. 2002 Sep-Oct;13(5):1112-8.
• [5] CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure. Naunyn Schmiedebergs Arch Pharmacol. 1990 Sep;342(3):305-11.
• [6] Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers. Clin Neuropharmacol. 1990 Oct;13(5):436-47.
• [7] Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. Schizophr Res. 2010 Sep;122(1-3):1-23.
• [8] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [9] Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase. J Med Chem. 2005 Dec 15;48(25):8070-8.
• [10] Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem. 2004 Dec 2;47(25):6207-17.
• [11] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.